• Policy
• Plan to build an information network to normalize the supply
• by Lee, Hye-Kyung Feb 22, 2023 05:54am

• Company
• Keytruda leads the market for 3 consecutive years
• by Chon, Seung-Hyun Feb 22, 2023 05:54am

• Company
• GC Biopharma receives WHO Pre-Qualification for Barycela
• by Kim, Jin-Gu Feb 21, 2023 05:52am

• Company
• 3rd PARPi Talzenna may be prescribed at hospitals in Korea
• by Eo, Yun-Ho Feb 21, 2023 05:52am

• Policy
• Severe Cancer Drug Benefits, covered by the National Budget
• by Lee, Jeong-Hwan Feb 20, 2023 05:53am

• Policy
• The Minister's willingness to innovate regulations
• by Lee, Hye-Kyung Feb 20, 2023 05:53am

• Company
• Organon ‘Samsung’s Humira biosimilar to make KRW 100 billi
• by Jung, Sae-Im Feb 20, 2023 05:53am

• Policy
• Will there be progress in introducing a checkup for Hep C?
• by Jung, Sae-Im Feb 20, 2023 05:52am

• Company
• Novartis’s Jakavi makes a step towards reimb for GvHD
• by Eo, Yun-Ho Feb 20, 2023 05:52am

• Policy
• Skyrizi benefit will be expanded from next month
• by Lee, Jeong-Hwan Feb 17, 2023 05:50am